Sunshine Biopharma, Inc. (SBFM)

NCM – Real vaqt narxi. Valyuta: USD

1.05

+0.02 (1.94%)

Yopilishda: May 12, 2026, 4:00 PM EDT

0.88

-0.17 (-16.19%)

Bozor oldidan: May 13, 2026, 6:38 AM EDT

06.04.2026

Sunshine Biopharma Reports Fiscal 2025 Revenue of $36.3 Million, a 4.1% Increase Over Prior Year

FORT LAUDERDALE, FL / ACCESS Newswire / April 6, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) ("Sunshine Biopharma" or the "Company"), a pharmaceutical company offering and developing life‑saving medicines across oncology, antivirals, and other key therapeutic areas, today announced the filing of its Annual Report on Form 10‑K for the fiscal year ended December 31, 2025. 2025 Highlights Revenue of $36.3 million, representing a 4.1% increase compared to 2024.

28.10.2025

Sunshine Biopharma Scores a Major Regulatory Win to Market Domperidone in Canada (NASDAQ: SBFM)

FORT LAUDERDALE, FL / ACCESS Newswire / October 28, 2025 / Momentum has a way of separating the contenders from the crowd. Sunshine Biopharma (NASDAQ: SBFM ) is quickly establishing which side of that line it's on.

28.10.2025

Sunshine Biopharma Gains FDA-Equivalent Clearance in Canada for Domperidone to Treat Cancer-related Nausea

FORT LAUDERDALE, FL / ACCESS Newswire / October 28, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company focused on innovative and affordable healthcare solutions, today announced that its wholly owned subsidiary, Nora Pharma Inc., has received approval from Health Canada, the Canadian equivalent to the FDA, for the commercialization of Domperidone, a prescription medication used to relieve nausea and vomiting and to enhance gastrointestinal motility. Domperidone is often used for chemotherapy-induced nausea and vomiting, especially when patients cannot tolerate other antiemetics which may cause extrapyramidal side effects.

20.10.2025

Sunshine Biopharma Launches STD, Acne and Lyme Disease Therapy Doxycycline

FORT LAUDERDALE, FL / ACCESS Newswire / October 20, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company focused on innovative and affordable healthcare solutions, today announced the commercial launch of generic Doxycycline in Canada. This strategic move strengthens the Company's footprint in the Canadian growing antibiotic sector.

Videolar

No Data

There is no data to display

Press-relizlar

06.04.2026

Sunshine Biopharma, Inc. (SBFM)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Sunshine Biopharma, Inc. (SBFM)

Sunshine Biopharma Reports Fiscal 2025 Revenue of $36.3 Million, a 4.1% Increase Over Prior Year

Sunshine Biopharma Scores a Major Regulatory Win to Market Domperidone in Canada (NASDAQ: SBFM)

Sunshine Biopharma Gains FDA-Equivalent Clearance in Canada for Domperidone to Treat Cancer-related Nausea

Sunshine Biopharma Launches STD, Acne and Lyme Disease Therapy Doxycycline

Videolar

No Data

Press-relizlar

Sunshine Biopharma Reports Fiscal 2025 Revenue of $36.3 Million, a 4.1% Increase Over Prior Year

Sunshine Biopharma Reports Fiscal 2025 Revenue of $36.3 Million, a 4.1% Increase Over Prior Year

Sunshine Biopharma Scores a Major Regulatory Win to Market Domperidone in Canada (NASDAQ: SBFM)

Sunshine Biopharma Gains FDA-Equivalent Clearance in Canada for Domperidone to Treat Cancer-related Nausea

Sunshine Biopharma Launches STD, Acne and Lyme Disease Therapy Doxycycline

Videolar

No Data

Press-relizlar

Sunshine Biopharma Reports Fiscal 2025 Revenue of $36.3 Million, a 4.1% Increase Over Prior Year

Sunshine Biopharma Scores a Major Regulatory Win to Market Domperidone in Canada (NASDAQ: SBFM)

Sunshine Biopharma Gains FDA-Equivalent Clearance in Canada for Domperidone to Treat Cancer-related Nausea

Sunshine Biopharma Launches STD, Acne and Lyme Disease Therapy Doxycycline

Search stocks

Sunshine Biopharma, Inc. (SBFM)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Sunshine Biopharma, Inc. (SBFM)

Sunshine Biopharma Reports Fiscal 2025 Revenue of $36.3 Million, a 4.1% Increase Over Prior Year

Sunshine Biopharma Scores a Major Regulatory Win to Market Domperidone in Canada (NASDAQ: SBFM)

Sunshine Biopharma Gains FDA-Equivalent Clearance in Canada for Domperidone to Treat Cancer-related Nausea

Sunshine Biopharma Launches STD, Acne and Lyme Disease Therapy Doxycycline

Videolar

No Data

Press-relizlar

Sunshine Biopharma Reports Fiscal 2025 Revenue of $36.3 Million, a 4.1% Increase Over Prior Year

Sunshine Biopharma Reports Fiscal 2025 Revenue of $36.3 Million, a 4.1% Increase Over Prior Year

Sunshine Biopharma Scores a Major Regulatory Win to Market Domperidone in Canada (NASDAQ: SBFM)

Sunshine Biopharma Gains FDA-Equivalent Clearance in Canada for Domperidone to Treat Cancer-related Nausea

Sunshine Biopharma Launches STD, Acne and Lyme Disease Therapy Doxycycline

Videolar

No Data

Press-relizlar

Sunshine Biopharma Reports Fiscal 2025 Revenue of $36.3 Million, a 4.1% Increase Over Prior Year

Sunshine Biopharma Scores a Major Regulatory Win to Market Domperidone in Canada (NASDAQ: SBFM)

Sunshine Biopharma Gains FDA-Equivalent Clearance in Canada for Domperidone to Treat Cancer-related Nausea

Sunshine Biopharma Launches STD, Acne and Lyme Disease Therapy Doxycycline